Event-Driven Stocks

Elevation Oncology, Inc.

ELEV

Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 2 good● 1 warning● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY24FY23FY22FY21FY20
Revenue—————
Operating income−$44.7M−$45.4M−$94.5M−$32.0M−$17.3M
Net income−$44.5M−$45.7M−$95.1M−$32.0M−$17.3M
Total assets$95.6M$89.1M$94.2M$149.5M$80.9M
Total liabilities$35.6M$34.3M$45.1M$8.8M$6.8M
Equity$60.0M$54.8M$49.0M$140.7M−$23.1M
EPS (diluted)$-0.78$-1.25$-4.09$-2.64$-21.80
Shares out.48.7M23.7M23.2M23.2M800,679

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2024
Operating margin
—
Net margin
—
Return on equity
−74.1%
Return on assets
−46.5%
Return on capital (ROCE)
−49.0%
Liabilities / assets
37.2%
Debt / equity
0.59×
Book value / share
$1.23
Revenue growth (YoY)
—
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2024
Altman Z″ (distress)
-3.38distress
Accruals / assets
−8.5%clean
Piotroski F-Score
3/7weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
52
/ 100
Profitability 0Growth n/aCatalyst 67Earnings quality 67Financial strength 75

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 severe● 1 warning● 2 good
  • Altman Z″ in the distress zone
  • Negative operating cash flow
  • Conservative leverage (liabilities < 50% of assets)
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
Jul 15, 20251.2M1.9-40.4%
Jun 30, 20252.1M1.6-31.5%
Jun 13, 20253.0M1.0+19.1%
May 30, 20252.6M3.3-42.3%
May 15, 20254.4M5.7+22.1%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (2)